Choosing the right pharmaceutical manufacturing partner is critical for success. At Cipro Pharmaceuticals, we bring together decades of expertise, a culture of quality, and a commitment to long-term collaboration. Here’s why partners trust us:
Backed by the legacy of the Srini Umbrella, we offer decades of proven expertise in pharmaceutical R&D, manufacturing, and regulatory compliance. This experience allows us to anticipate industry challenges, adapt to evolving standards, and deliver solutions that stand the test of time.
Quality is embedded across every stage of our operations—from raw material handling to finished-product testing. Our facility complies with WHO GMP and TGA standards, ensuring that every formulation meets stringent global requirements. This unwavering focus on quality builds confidence among healthcare providers and patients alike.
Our facility at Mallapur, Hyderabad, is equipped to handle scale-up processes and commercial production across multiple therapeutic categories. With robust infrastructure and validated processes, we ensure consistency, efficiency, and the ability to meet large-scale demand without compromising quality.
Led by Dr. T. C. Reddy, a distinguished chemical engineer with over three decades of experience, our leadership combines deep scientific knowledge with strategic vision. This expertise drives innovation in formulation development and strengthens our ability to deliver reliable pharmaceutical solutions.
We believe in building long-term, win-win collaborations. Our approach is rooted in transparency, compliance, and responsiveness. By aligning with our partners’ goals, we create sustainable relationships that foster innovation, efficiency, and shared success.
At Cipro Pharmaceuticals, our commitment goes beyond manufacturing medicines—it reflects our values, our vision, and our responsibility to healthcare. We stand firmly for principles that define who we are and how we operate.
Quality is the cornerstone of our operations. Every product is developed and manufactured under stringent WHO GMP and TGA-compliant processes, ensuring safety, efficacy, and consistency. We embed quality into every stage—from raw material handling to finished-product release—so our partners and patients can trust in what we deliver.
We believe innovation drives progress. Through R&D, formulation development, and process optimization, we continuously explore new ways to improve pharmaceutical solutions. Innovation at Cipro is not just about new products—it’s about smarter processes, advanced technologies, and better healthcare outcomes.
Integrity defines our culture. We conduct business with transparency, responsibility, and ethical practices, ensuring compliance with global regulations. Our commitment to integrity builds trust with partners, regulators, and communities, reinforcing our reputation as a reliable pharmaceutical manufacturer.
Reliability means delivering on our promises. With robust infrastructure and validated processes, we ensure consistent manufacturing performance and dependable supply chains. Our partners can rely on us for timely delivery, regulatory compliance, and unwavering product quality.
We embrace a culture of continuous improvement. By evaluating processes, adopting new technologies, and refining systems, we strengthen efficiency and enhance quality. This commitment ensures that we remain agile, competitive, and aligned with evolving healthcare needs.
Together, these values—quality, innovation, integrity, reliability, and continuous improvement—form the foundation of our promise: To be a trusted pharmaceutical partner that consistently delivers excellence, supports healthcare progress, and builds long-term collaborations worldwide.
• 1995: Foundation of Srini Pharma
• 2005: Establishment of Cipro Pharmaceuticals
• 2017: The facility was accredited by TGA and initiated the commercialization
• 2019: The facility was accredited by TGA
• 2019: The facility was accredited by WHO - GMP
• 2020: The facility was accredited by TGA
• 2023: The facility was accredited by TGA
• Today: Planning to Audit triggering for EU-GMP and expanding capabilities injectable lines facility for pharmaceutical manufacturing and global partnerships